CJC-1295 Side Effects: Short Follow-Up Leaves Questions
The Short Version: Brief Testing Can’t Establish Lasting Safety
An experimental compound, CJC-1295 raises growth-related hormones. Here's what reactions and short follow-up mean for you.
The two studies involved 24 healthy adults altogether, followed for at most 49 days. Published safety follow-up doesn't extend beyond 3 months [16].
During the Teichman 2006 trial, study amounts were 30–125 micrograms per kilogram, based on weight [13]. A gram contains a million units called micrograms; reactions during testing were mild, with none reported as serious.
About 23% had redness at the shot site, and about 22% had brief flushing or dizziness. Headaches also appeared with larger CJC-1295 study amounts.
Volunteers reported fewer problems with 30–60 micrograms per kilogram, without establishing safety in your care. That comparison didn't test your other medicines or health problems.
Other reports mention swelling, facial flushing, brief headaches, and reactions at the shot site. The FDA's 2024 review also described rare heart effects, including faster heartbeat and widened blood vessels.
The short CJC-1295 trial gives some reassurance about reactions during the period studied [13]. I'd ask your doctor which new symptoms would need a call, how your health would be followed, and whether concerns would mean another visit or blood test for your particular health needs.
Extra Salt and Water Can Explain Swelling
Reports and small early CJC-1295 studies often describe swelling. Those CJC-1295 accounts aren't enough to establish how often you'd have swelling.
With more growth hormone, your kidneys may hold onto salt, and water stays alongside that salt [8]. Other compounds that raise growth hormone can also cause that effect.
Larger amounts tend to bring more swelling in those findings. Swelling usually eased after use stopped in animals, but that doesn't predict your response.
CJC-1295 Left Usual Hormone Bursts Continuing During Testing
The study was brief, leaving lasting changes in hormone release unknown. Ionescu and Frohman 2006 found the gland beneath the brain kept its usual growth hormone bursts during CJC-1295 testing [2].
CJC-1295 prompts that gland to release hormone, while growth hormone shots can reduce its own release. The level between bursts rose without changing each burst's timing or size.
Teichman's 2006 study didn't report reduced growth hormone during 28-day or 49-day follow-up [18]. Effects after more than three months of use weren't established by that testing.
The Pair’s Reaction Rates Haven’t Been Measured
Ipamorelin also prompts growth hormone release, and people sometimes pair that compound with CJC-1295. No published study has compared that pair with an untreated group to measure side effects.
Concerns about more swelling, flushing, and shot reactions come from findings about CJC-1295 alone [13]. Greater growth hormone release might worsen those effects, but the pair hasn't been tested to show that.
Your doctor can distinguish an expected problem from one measured in people receiving both compounds. Ask which kind of evidence supports a claim about the pair's risks.
Research Users Describe Sleep Trouble That Remains Untested
People using CJC-1295 without DAC for research have described vivid dreams and brief sleep trouble. These experiences and small patient reports weren't checked against an untreated group; a trial hasn't tested the claimed sleep effects.
Some reports mention shots given near bedtime, when deep sleep normally brings growth hormone release. An extra burst then might change sleep, but that explanation hasn't been proved.
Published sleep studies haven't tested this form against a placebo, a shot without CJC-1295. You don't have evidence that the shorter-lasting form would improve your sleep.
Leaving an FDA Safety List Didn’t Give Approval
CJC-1295 hasn't received FDA approval for any use. In December 2024, the agency's pharmacy panel reviewed CJC-1295 for medicines mixed for individual patients.
The FDA raised concerns about clumps and unwanted material triggering an immune system reaction [16]. Your body's defenses can react to unwanted material in a shot.
The people who requested that review later withdrew their request. On FDA's page current as of April 22, 2026, CJC-1295 isn't listed in Category 2, a list of pharmacy ingredients with safety concerns.
That page date doesn't tell you when the listing changed, and withdrawal wasn't approval. The FDA hasn't explained what the withdrawal permits a pharmacy to do with CJC-1295.
WADA, which sets banned drug rules in sport, prohibits the compound under its 2024 rules. Ask your doctor how those FDA concerns bear on any care you're discussing.